Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Omeros's Business Segments
Omeros's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Royalties on Sales of Yartemlea
Total Revenue
$ 40
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Royalties on Sales of Yartemlea0.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalties on Sales of Yartemlea | $ 0 | 0.8% |
Annual Results
Revenue Share by Reportable Segment - FY
- Royalties on Sales of Yartemlea0.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalties on Sales of Yartemlea | $ 0 | 0.8% |
Description of Omeros
Omeros Corporation is a biopharmaceutical company that is headquartered in Seattle, Washington. The company is focused on identifying, developing, and commercializing therapeutics for a range of medical conditions that affect the eye, as well as the central nervous system (CNS), and immune-mediated diseases.
The company's lead product candidates are OMS302, OMS721, and OMS82 OMS302 is designed for use during cataract surgery and is a combination of two drugs - phenylephrine and ketorolac - that are intended to reduce inflammation, inhibit pupil constriction, and provide pain relief. OMS721 is an investigational human monoclonal antibody that targets a protein called MASP-2, which is believed to be involved in the development of certain renal and hematologic disorders. And OMS824 is being developed as a potential treatment for schizophrenia, Huntington's disease, and other CNS disorders.
In addition to these lead product candidates, Omeros has multiple programs in preclinical and clinical development for a variety of indications, including complement-mediated diseases, addiction, and acute pain.
The company's technology platform involves their proprietary PharmacoSurgery platform, which is designed to provide a unique combination of pharmacology and surgery in one setting. This approach facilitates improved surgical outcomes and reduced recovery times for patients.
Omeros has established relationships with various partners, including surgery centers, pharmaceutical companies, and academic institutions, to facilitate their research and development efforts. They have also received support from government agencies, such as the National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse.
Overall, Omeros Corporation is committed to advancing their research and development efforts to meet the unmet needs of patients with a range of medical conditions.
The company's lead product candidates are OMS302, OMS721, and OMS82 OMS302 is designed for use during cataract surgery and is a combination of two drugs - phenylephrine and ketorolac - that are intended to reduce inflammation, inhibit pupil constriction, and provide pain relief. OMS721 is an investigational human monoclonal antibody that targets a protein called MASP-2, which is believed to be involved in the development of certain renal and hematologic disorders. And OMS824 is being developed as a potential treatment for schizophrenia, Huntington's disease, and other CNS disorders.
In addition to these lead product candidates, Omeros has multiple programs in preclinical and clinical development for a variety of indications, including complement-mediated diseases, addiction, and acute pain.
The company's technology platform involves their proprietary PharmacoSurgery platform, which is designed to provide a unique combination of pharmacology and surgery in one setting. This approach facilitates improved surgical outcomes and reduced recovery times for patients.
Omeros has established relationships with various partners, including surgery centers, pharmaceutical companies, and academic institutions, to facilitate their research and development efforts. They have also received support from government agencies, such as the National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse.
Overall, Omeros Corporation is committed to advancing their research and development efforts to meet the unmet needs of patients with a range of medical conditions.
Omeros Corporation is a prominent biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic products, particularly focusing on inflammation and complement-mediated diseases. With a singular reportable segment, Omeros emphasizes the robust advancement of pharmaceutical solutions aimed at addressing multiple significant medical conditions. The structure of Omeros Corporations offerings can be categorized extensively into three key domains: Commercial Products, Development Products, and Research Programs.
1. Commercial Products
Omidria (phenylephrine and ketorolac injection): This is Omeros’ inaugural commercial product and the first of its kind approved by the FDA for ophthalmic surgeries. Specifically, Omidria is utilized during cataract surgery to maintain pupil size and to mitigate intraoperative miosis (the constriction of the pupil). It achieves this by combining phenylephrine, a mydriatic agent, with ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) that helps alleviate postoperative pain. The unique combination addresses two crucial intraoperative challenges, increasing surgical efficiency and improving patient outcomes. Omidria has been pivotal in enhancing the surgical experience for both ophthalmic surgeons and their patients and is marketed as an innovative solution in the surgical suite.
Development Products
Omeros is advancing several promising candidates in its development pipeline, aimed at addressing various complex diseases associated with complement activation and other disease mechanisms:
MASP-2 Inhibitor OMS906: This investigational drug is currently undergoing development for treating complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy, among others. By inhibiting the MASP-2 protein, OMS906 aims to interrupt the complement cascade, which can play a critical role in the pathophysiology of these diseases.
GPR174 Inhibitor OMS527: This product is in development to address substance use disorders and is specifically being evaluated for its effectiveness in treating addictions associated with various substances, including nicotine, opioids, methamphetamines, cocaine, and alcohol. By targeting the GPR174 receptor, OMS527 holds the potential to modulate neurobiological pathways associated with addiction.
MASP-3 Inhibitor OMS906: This candidate builds upon the MASP-2 inhibitor by simultaneously blocking both MASP-2 and MASP-3, thus intervening in the complement system at an earlier stage compared to other treatments. This dual-inhibition strategy aims to provide a more comprehensive approach to managing diseases tied to complement dysregulation.
Research Programs
Omeros is also engaged in a wide array of research programs, which encompass both preclinical and early-stage clinical development across several therapeutic areas. This pipeline is characterized by:
- Conditions linked to the immune system, such as immune thrombocytopenic purpura (ITP) and autoimmune diseases.
- Liver diseases, both acute and chronic, offering potential interventions to alter disease progression.
- Neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease, and traumatic brain injury (TBI), where promising targets for intervention are being explored.
- Diabetic retinopathy, where new methods of intervention may help mitigate ocular complications associated with diabetes.
Through these research initiatives, Omeros seeks to innovate and expand the frontiers of treatment for conditions traditionally difficult to manage.
Services Offered
Beyond its pharmaceutical products, Omeros provides a suite of services that aid in the development and commercialization of therapeutic candidates. The Discovery Biology services include:
- Target Discovery and Validation: Identifying and validating biological targets for new drugs.
- Hit-to-Lead Optimization: Enhancing the properties of identified hits to develop viable lead compounds for further testing.
- Preclinical Pharmacology: Conducting essential studies to inform the pharmacological profile of drug candidates prior to clinical studies.
Additionally, Omeros offers development services designed to assist other companies in the necessary stages of bringing their product candidates to market. This comprehensive approach not only showcases Omeros capabilities as an innovator but also positions it as a valuable partner for other entities within the biopharmaceutical landscape.
Summary
In conclusion, Omeros Corporation is firmly positioned at the intersection of innovation and patient care, offering a robust portfolio of commercial and developmental products along with essential research services. With a keen focus on inflammation, autoimmune conditions, and complement-mediated diseases, the company remains dedicated to pioneering new treatments to improve health outcomes for diverse patient populations. Omeros continues to expand its efforts, enhancing its capabilities to address significant unmet medical needs and to develop solutions that provide tangible benefits to patients worldwide.
1. Commercial Products
Omidria (phenylephrine and ketorolac injection): This is Omeros’ inaugural commercial product and the first of its kind approved by the FDA for ophthalmic surgeries. Specifically, Omidria is utilized during cataract surgery to maintain pupil size and to mitigate intraoperative miosis (the constriction of the pupil). It achieves this by combining phenylephrine, a mydriatic agent, with ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) that helps alleviate postoperative pain. The unique combination addresses two crucial intraoperative challenges, increasing surgical efficiency and improving patient outcomes. Omidria has been pivotal in enhancing the surgical experience for both ophthalmic surgeons and their patients and is marketed as an innovative solution in the surgical suite.
Development Products
Omeros is advancing several promising candidates in its development pipeline, aimed at addressing various complex diseases associated with complement activation and other disease mechanisms:
MASP-2 Inhibitor OMS906: This investigational drug is currently undergoing development for treating complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and IgA nephropathy, among others. By inhibiting the MASP-2 protein, OMS906 aims to interrupt the complement cascade, which can play a critical role in the pathophysiology of these diseases.
GPR174 Inhibitor OMS527: This product is in development to address substance use disorders and is specifically being evaluated for its effectiveness in treating addictions associated with various substances, including nicotine, opioids, methamphetamines, cocaine, and alcohol. By targeting the GPR174 receptor, OMS527 holds the potential to modulate neurobiological pathways associated with addiction.
MASP-3 Inhibitor OMS906: This candidate builds upon the MASP-2 inhibitor by simultaneously blocking both MASP-2 and MASP-3, thus intervening in the complement system at an earlier stage compared to other treatments. This dual-inhibition strategy aims to provide a more comprehensive approach to managing diseases tied to complement dysregulation.
Research Programs
Omeros is also engaged in a wide array of research programs, which encompass both preclinical and early-stage clinical development across several therapeutic areas. This pipeline is characterized by:
- Conditions linked to the immune system, such as immune thrombocytopenic purpura (ITP) and autoimmune diseases.
- Liver diseases, both acute and chronic, offering potential interventions to alter disease progression.
- Neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS), Huntington’s disease, and traumatic brain injury (TBI), where promising targets for intervention are being explored.
- Diabetic retinopathy, where new methods of intervention may help mitigate ocular complications associated with diabetes.
Through these research initiatives, Omeros seeks to innovate and expand the frontiers of treatment for conditions traditionally difficult to manage.
Services Offered
Beyond its pharmaceutical products, Omeros provides a suite of services that aid in the development and commercialization of therapeutic candidates. The Discovery Biology services include:
- Target Discovery and Validation: Identifying and validating biological targets for new drugs.
- Hit-to-Lead Optimization: Enhancing the properties of identified hits to develop viable lead compounds for further testing.
- Preclinical Pharmacology: Conducting essential studies to inform the pharmacological profile of drug candidates prior to clinical studies.
Additionally, Omeros offers development services designed to assist other companies in the necessary stages of bringing their product candidates to market. This comprehensive approach not only showcases Omeros capabilities as an innovator but also positions it as a valuable partner for other entities within the biopharmaceutical landscape.
Summary
In conclusion, Omeros Corporation is firmly positioned at the intersection of innovation and patient care, offering a robust portfolio of commercial and developmental products along with essential research services. With a keen focus on inflammation, autoimmune conditions, and complement-mediated diseases, the company remains dedicated to pioneering new treatments to improve health outcomes for diverse patient populations. Omeros continues to expand its efforts, enhancing its capabilities to address significant unmet medical needs and to develop solutions that provide tangible benefits to patients worldwide.